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Joshua C. Grimm, J. Trent Magruder, Clinton D. Kemp and Ashish S. Shah*
Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA
Left ventricular assist devices have become standard therapy for patients with end-
stage heart failure. They represent potential long-term solutions for a growing public
health problem. However, initial enthusiasm for this technology has been tempered by
challenges posed by long-term support. This review examines these challenges and out
current understanding of their etiologies.
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Introduction
Technological advances have allowed for the emergence of newer generation, continuous-flow left
ventricular assist devices (LVADs) approved for both bridge-to-transplant (BTT) as well as destina-
tion therapy (DT) in patients with end-stage heart failure. As outlined in the Third INTERMACS
Annual Report, there has been a recent trend toward a greater number of devices being implanted
in patients with an initial strategy of DT support (1). The Sixth INTERMACS Annual Report
quantified further and demonstrated a nearly three-fold increase from 2006–2007 to 2011–2013
(14.7 and 41.6%, respectively) (2). Within this cohort of patients implanted between 2006 and 2010,
approximately 80% were deemed INTERMACS level 2 (progressive decline), 3 (stable but inotrope-
dependent), or 4 (recurrent, advanced heart failure) (1, 3), and as they did not represent “crash and
burn” patients (INTERMACS level 1), expected short-term survivals were improved (4, 5).
Accordingly, while early complications following LVAD implantation have been extensively
described and have been shown to greatly impact perioperative morbidity and mortality (6–8), it is
reasonable to expect that the influence of late adverse events will be increasingly more relevant given
the changing landscape of these implantable circulatory support devices. The following review will
explore the long term, systemic effects of prolonged, continuous-flow LVAD support (device failures,
bleeding, right ventricular dysfunction, infection, aortic valve pathology, and thromboembolic
events) and briefly describe the most common management strategies employed in each scenario.
Technical, Device Failures
Failure of modern, continuous-flow LVADs is exceedingly rare but can involve any component of
the device (i.e., pump, controller, or power source). It is critically important that an emergency
card is visible at all times when a patient is discharged to home with a LVAD. This will provide
invaluable information to first responders in cases of device failure. More specifically, problems with
the power source can typically be mitigated by a VAD coordinator or outpatient nurse as they are
easily exchangeable without the need for an invasive procedure.
Abbreviations: BTT, bridge-to-transplant; DT, destination therapy, GI, gastrointestinal, LVAD, left ventricular assist devices,
vWF: von Willebrand factor.
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If, however, the pump or the internal portion of the cable is the
culprit, an emergent and operative exchange is required. In these
instances, profound cardiogenic shock can develop and temporary
extracorporeal support might be necessary. The reported inci-
dence of pump thrombosis in modern, continuous-flow devices
ranges from 0.01 to 0.11 events per patient-year, but these figures
likely represent underestimates as clinically silent thrombi often
go undetected and not all devices are interrogated following
explant (8–10). Factors, such as atrial fibrillation, sub-therapeutic
systemic anticoagulation, and infection, have been associatedwith
increases in device thrombosis.
Since 2011, the incidence of HeartMate II® (Thoratec Corp.,
Pleasanton, CA) thrombosis has seen a dramatic increase from
roughly 2 to 8% by January 2013 (9). Participating investigators
theorized that this phenomenon was largely attributable to the
“bearing-fibrin deposition theory”, which occurs in three distinct
phases: (1) an initial phase characterized by hemolysis and throm-
bus deposition (termed “thrombus formation”); (2) “incomplete
thrombus” resulting in red-cell destruction and abnormalities in
LVAD performance; and (3) “complete thrombosis” culminat-
ing in device failure (9). While no unifiable factors were iden-
tified, flow reduction, whether due to arrhythmia, aortic regur-
gitation, or outflow obstruction, is an important element of the
pathophysiology.
While there remains no consensus regarding the most sensi-
tive and specific marker for early detection of imminent pump
thrombosis, some have proposed a serum lactate dehydroge-
nase (LDH) level >4 normal (10) in combination with suspi-
cious echocardiographic findings. While this value might capture
patients with frank thrombosis, it might miss more subtle, earlier
indicators of an impending problem at a time in which interven-
tion might prove beneficial. Accordingly, LDH values>2.5 nor-
mal should prompt further interrogation with additional serum
values [hemoglobin, haptoglobin, creatinine, total bilirubin, and
international normalized ratio (INR)], chest X-ray, and a trans-
esophageal echocardiogram. The latter can be utilized to evaluate
the position of the cannula in respect to the ventricular walls and
mitral valve. Additionally, if the aortic valve continues to open in
response to incremental increases in the LVAD speed (ramp test),
thus denoting incomplete emptying of the left ventricle, pump
thrombosis should be suspected.
In the initial stages of device thrombosis, and assuming patient
stability, non-operative management should be attempted. The
patient should be started on a heparin infusion to halt propagation
of the thrombus and to augment fibrinolysis. Active resuscita-
tion should also be pursued, with or without force diuresis, to
combat the detrimental effects of hemolysis on renal function.
The patient should be closely monitored in a cardiac intensive
care unit for signs of decompensation that might require urgent
surgical management. In order to minimize the risk of pump
thrombosis, patients should undergo a ramp study during their
index hospitalization to provide a baseline for further evaluations.
Anticoagulant and antiplatelet therapy should be implemented
with an INR goal of 2–3.
In a large study that retrospectively examined approximately
1,200 devices, the rate of driveline fracture was 9.2% (11). A
majority of these cases (87%) were isolated to the external portion
of the cable and reinforcement was successful in most instances
(76%) (11).
Bleeding
Hemorrhage is one of the most common and challenging early
and late complications associated with LVADs. The incidence of
bleeding, whether requiring reoperation or red cell transfusion, is
0.16–2.45 events per patient-year (12, 13). The etiology of these
events is multifactorial and includes: (1) management with sys-
temic anticoagulation to diminish the risks of pump thrombosis
and thromboembolic phenomena, (2) acquired von Willebrand
Syndromedue to the non-physiologic, high-shear stress associated
with the low-pulse pressures of continuous-flow devices (14, 15),
and (3) the appearance of arteriovenous malformations (AVMs)
(16, 17). While a majority of early episodes involves intratho-
racic and/or mediastinal hemorrhage, the importance of these as
causative factors diminishes over time. Conversely, the gastroin-
testinal (GI) tract is the principal source of late hemorrhage and,
accordingly, a familiar effector of hospital readmission (14, 18).
Several studies have demonstrated a growing rate of clinically
relevant GI bleeds with the advent of continuous-flow devices (19,
20).While this association ismost likely a combined result ofman-
ufacturer recommendations and guidelines of the HeartMate II
Pivotal Trial to utilize antiplatelet medications and anticoagulants
in LVAD patients to mitigate the up-regulation of the coagulation
cascade, the observed rate was higher than would be attributable
to systemic therapies alone (19).
Awareness of additional mechanisms that may contribute to
this increased incidence of GI events has been the focus of several
recent studies (14, 17). A sub-analysis of the HVADBTT and CAP
trials demonstrated a 15.4% incidence of GI bleeding with 86.1%
of these events occurring>30 days from the initial operation (14).
It is important to note that while the mean INRs were higher in
those experiencing a bleed (2.4 vs. 1.6, p< 0.0001), a frank lesion,
with an AVM being the most common, was identified as the cause
of hemorrhage in 78% of the events (14). The pathophysiology
associated with the development of these malformations is similar
to the mechanism implicated in severe aortic stenosis (21). More
specifically, a decrease in pulse pressure in these continuous-
flow devices could result in relative splanchnic hypoperfusion and
increased vessel friability. Another proposed theory to explain the
high frequency of AVMs in this demographic involves the influ-
ence of increased intraluminal pressures, simultaneous vascular
smooth muscle contractions, and subsequent relaxations of the
bowel wall smooth muscle (16, 17).
In addition to adversely affecting vessel integrity, continuous-
flow LVADs have been associated with acquired von Willebrand
Syndrome (15, 20, 22). The biologic activity of von Willebrand
factor (vWF) depends upon the cleavage of this molecule at a
specific site by the ADAMTS13 metalloprotease and in order
to promote normal coagulation, it is crucial to maintain equi-
librium of the vWF multimer size. Studies have demonstrated
that in situations of high-shear stress, the vWF multimers can
undergo a conformational change, leading to an over-exposure of
the cleavage domain. The shear forces on the artificial surfaces
of these mechanical devices may deplete these larger multimers
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due to aberrant cleavage by ADAMTS13 and result in bleeding
abnormalities (15, 20, 22).
Most GI bleeds require hospitalization, cessation of anticoagu-
lation/antiplatelet therapies, institution of acid-reflux agents, and
close hemodynamic and laboratory monitoring. Patients should
be promptly evaluated by a Gastroenterologist for possible endo-
scopic management. Fortunately, several large studies have estab-
lished that surgical intervention is rarely, if ever, a component
of the treatment algorithm (14). These events are associated,
however, with readmissions, non-device related infections, and
subsequent thromboembolic complications (13, 14).
Several studies have supported a reduction in the target INR
to 1.5–2.5 following a major GI bleed as most events are asso-
ciated with an INR 2.5 (23). Unless the patient has had mul-
tiple life-threatening hemorrhagic events, complete cessation of
anticoagulants and antiplatelet therapies is not recommended. In
a meta-analysis evaluating risk factors associated with GI hem-
orrhage, nine of the studies included reported that a majority
of the HeartMate II patients had therapeutic or sub-therapeutic
INRs (24).
Right Ventricular Dysfunction
Right ventricular dysfunction occurs in 9–44% of patients
following LVAD implantation and is a significant contributor of
short- and long-term morbidity and mortality (25–27). An initial
examination into the comparative incidence of this condition
in patients managed with pulsatile and continuous-flow device
demonstrated no significant difference (28). Acute right heart
failure is typically attributable to pre-LVAD organ system dys-
function [as indicated by the need for mechanical ventilation (29)
or elevations in serum bilirubin and/or creatinine (30)] and/or
marginal right ventricular function at the time of implant (27, 29).
Amore insidious, chronic form of right ventricular dysfunction
has also been identified, but its pathogenesis is poorly character-
ized. Multiple studies have demonstrated a leftward excursion of
the intraventricular septum due to a reduction in left ventricular
pressure and augmentation of right ventricular preload in patients
supported by a LVAD (30, 31). These physiologic alterations are
typically well tolerated and can even create a favorable pressure
profile. In selected patients with marginal right ventricular func-
tion, however, even small variations in right-sided compliance
can result in an inability to tolerate an increase in venous return.
Conventional management strategies involve the assessment of
flow through the device to normalize septal shift and the intro-
duction of agents to minimize right ventricular afterload. The
need for biventricular support in patients with severe right-sided
impairment confers a considerably worse prognosis (27). In BTT
patients with right ventricular dysfunction recalcitrant to medical
management, heart transplantation should be strongly considered
to avoid further deterioration of end-organ function.
Infection
As per the INTERMACs Registry, LVAD-associated infections are
categorized as follows: (1) localized non-device infection – infec-
tion involving an organ or region without evidence of systemic
involvement; (2) pump infection – infection involving any compo-
nent of the pump (pump or inflow or outflow cannulae); and (3)
percutaneous site and/or pocket infection – positive culture from
the tissue surrounding either the external portion of the driveline
or the housing of the device. The latter has been largely attributed
to trauma around the exit site that disrupts the tissue-line interface
(32). In a large institutional series of 143 HeartMate II patients,
driveline infections were diagnosed in approximately 12% of the
population (33). The odds of developing an infection increased
approximately 4% for each additional month of LVAD support
(33). Progression to pocket or pump involvement was rare.
The incidence of driveline, pump pocket, or pump infection has
diminished with the advent of newer generation, smaller axial-
flow LVADs (e.g., driveline infections: 0.37 vs. 3.49 events per
patient-year in HeartMate I and HeartMate II devices, respec-
tively) (34). Furthermore, while the exact etiology is unknown,
substantial reductions in infectious complications have also been
appreciated in the recent era of continuous-flow implants (10.0 vs.
1.3 events per 100 patient-months, p< 0.001) (2). Most cases are
successfully treated with antibiotic therapy and reinforcement of
the exit site. More complex infections required surgical debride-
ment in addition to medical management. Despite their varying
clinical implications, these infections should not be trivialized as
they are associated with costly readmissions and increased length
of stay (32).
Patients should be educated on the importance of recognizing
and reporting any traumatic events associated with the driveline
as even small shear forces are capable of inciting an infectious
complication. Some infections can be treated on an outpatient
bases with a combination of intravenous and oral antibiotics that
cover themost commonpathogens, namely Staphylococcus species
(32, 33). In patients who were present with noticeable cellulitis
and other markers of infection, e.g., fever and leukocytosis, hos-
pital admission and further workup are more appropriate. Blood
cultures, aspirates for Gram stain and culture, and tissue samples
should be collected if clinically indicated. If a deeper infection
is suspected, abdominal ultrasound or CT imaging might be
warranted.
If conservative management is not successful, then complete
circumferential excision of all neo-epithelized tissue is required.
Excision should continue until a tight adherence between the driv-
eline and surrounding tissue is apparent. If the infection involves
the pump pocket, external drainage can be attempted, but is often
times unsuccessful. Surgical management of these infections can
be difficult and multiple operations might be required to salvage
the device.
Aortic Valve Pathology
LVADs efficiently unload the left ventricle and diminish open-
ing/closing of the aortic valve, which can result in progressive
degeneration and a variety of valvular pathologies (35–37). This
untoward consequence of chronic support can have deleterious
effects on end-organ function and complicate cardiac recovery.
The aortic valve is especially susceptible to acquired defects as its
opening is entirely dependent upon forward flow from the left
ventricle.
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In a small series of patients with a mean LVAD time of approx-
imately 1 year, commissural fusion was evident in all but one
patient (38). The number of patients experiencing any aortic
valve opening on echocardiogram diminished as the duration
of support increased, with less than 50% having any valvular
motion at 1 year (38). These morphological changes commonly
resulted in mild to moderate central aortic regurgitation. Extrap-
olating from the heart failure population in which a diminished
cardiac-output results in continued leaflet co-aptation, it has been
postulated that continuous-flow LVADs create an environment
of minimal-antegrade blood flow across the aortic valve (39).
Furthermore, due to the placement of the outflow cannula in the
ascending aorta, the closed valve is constantly exposed to a systolic
pressure (40).
Device implantation can also result in a worsening of valvular
competence, especially in patients with pre-existing aortic insuffi-
ciency (40, 41). Due to the small size of the outflow cannula rela-
tive to the native aorta, higher velocities are required to maintain
physiologic flow rates (42). This can produce areas of high-shear
stress and initiate a cascade of cellular events which culminates
in aortic wall atrophy and sinus dilatation (37). These alterations
might have a more profound effect in smaller patients with pre-
sumably narrower aortic diameters. Regardless, regurgitant flow
can lead to further ventricular dilatation, increased pump work,
and systemic hypoperfusion.
The clinical ramification of these valvular abnormalities is
currently unknown. It is clear, however, that aortic valve dis-
ease in patients not destined for heart transplantation can
lead to further deterioration in ventricular function and make
device explantation less likely. Thus, there is a growing body
of literature supporting ramp studies at the time of implant
to ensure some aortic valve opening to reduce the long-term
implications of prolonged valve closure (43). In LVAD candi-
dates with baseline regurgitation or stenosis, concomitant aor-
tic valve procedures should be considered. In cases of mild
or worse regurgitation, a coaptive stitch can be attempted to
regain valve competence. If the native valve cannot be repaired,
a bio-prosthesis should be employed to restore proper valve
mechanics.
Thromboembolic Events
As previously mentioned, continuous-flow devices alter the equi-
librium of the coagulation cascade and can predispose patients
to thromboembolic phenomenon. It was initially believed that
the blood–biomaterial interaction within the LVAD was the main
stimulus for these findings (44), but surface modifications did
not appear to alleviate the problem (45). More contemporary
mechanisms involve the influence of the rotational flow of blood
through the pump on thrombus formation. Additional patient-
specific factors, including preoperative atrial fibrillation, have
been shown to increase the risk for post-LVAD thromboembolic
events (46).
While the true incidence of thromboembolic disease is hard
to approximate given that confirmatory radiographic studies are
typically only obtained in patients with frank neurologic impair-
ment, series have estimated that this condition affects 10–17% of
patients over the life time of their device (47, 48). These figures
likely underestimate the true impact of LVADs on embolic forma-
tion as evident by a limited study which identified microembolic
disease via transcranial Doppler in 20 out of 23 continuous-flow
LVAD patients (45). The nidus of these thrombi is variable but
the influence of aortic valve opening/closing on aortic root stag-
nation could emerge as an important factor in newer generation
devices. To combat thrombus formation,most patients are admin-
istered a combination of anticoagulants and antiplatelet agents.
Due to an increased risk of GI bleeding associated with greater
periods of support, several studies have demonstrated acceptable
thromboembolic protection with a more liberal anticoagulation
strategy (49).
Conclusion
Continuous-flow LVADs offer patients with advanced heart fail-
ure a viable option for prolonged support. As a growing number
of patients are maintained on these devices for longer periods, the
impact of late complications on outcomes will become increas-
inglymore relevant. Providers should be aware of these potentially
morbid events as prompt diagnosis and treatment are critical.
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